Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective

Patients with hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer constitute about 70% of the breast cancer population. About 35% of these patients develop distant metastases and their treatment will be palliative. Cyclin-dependent kinase 4 and 6 (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziobro, Marek, Grela-Wojewoda, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953114/
https://www.ncbi.nlm.nih.gov/pubmed/36831045
http://dx.doi.org/10.3390/biomedicines11020510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953114/
https://www.ncbi.nlm.nih.gov/pubmed/36831045
http://dx.doi.org/10.3390/biomedicines11020510

Ejemplares similares